Lm-LLO-Based Immunotherapies and HPV-Associated Disease

Table 3

Percent of intratumoral Tregs in a TC1 model following treatment with Lm-E7 and Lm-LLO-E7 in mouse model of cervical cancer [20].

Percent intratumoral Tregs by vector type
Lm-E7		Lm-LLO-E7
Spleen	Tumor	Spleen	Tumor
6.4	12.1	4.5	2.3
7.0	12.2	3.9	2.0
6.9	14.9	4.5	1.1
6.5	8.9	3.9	1.3